Optimizing Targeted Temperature Management in Comatose Cardiac Arrest Survivors

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  JAMA. https://doi.org/10.1001/jama.2026.10247  
Dr. William J. Meurer  et al.

Points

More than 250,000 Americans experience out-of-hospital cardiac arrest annually, with non-survival rates reaching approximately 90 percent.
University of Michigan researchers led the ICECAP trial across 71 hospitals from 2020 to 2025 to evaluate cooling durations.
The multicenter trial enrolled 1,158 adult cardiac arrest survivors subjected to therapeutic hypothermia lasting between six and 72 hours.
Results demonstrated that extending cooling durations beyond standard protocols did not improve patient survival or neurological recovery outcomes.
Comatose survivors with nonshockable rhythms demonstrated higher survival rates than previously reported, with some patients awakening after two weeks.

Summary

This study evaluated the efficacy of varying durations of therapeutic hypothermia for neuroprotection in comatose adult survivors of out-of-hospital cardiac arrest (OHCA). Each year, more than 250,000 individuals experience an OHCA in the United States, with an overall mortality rate approaching approximately 90%. While targeted temperature management slows metabolic demand to mitigate ischemia-reperfusion brain injury, optimal cooling duration has remained clinically uncertain. Led by Robert Silbergleit and William Meurer at the University of Michigan, the ICECAP trial sought to determine whether extending hypothermia protocols beyond standard timeframes improves neurological recovery across diverse patient cohorts.

Conducted across 71 U.S. hospitals between 2020 and 2025, the multicenter randomized clinical trial enrolled 1,158 comatose adult OHCA patients presenting with varying injury severity, including both shockable and nonshockable rhythms. Enrolled participants underwent controlled therapeutic hypothermia protocols ranging from 6 to 72 hours. Trial design incorporated both sudden cardiac arrest cases and nonshockable arrests following prolonged resuscitation, addressing historical uncertainties regarding baseline disease heterogeneity and post-cardiopulmonary resuscitation neurological recovery trajectories.

Systematic evaluation demonstrated that extending therapeutic hypothermia durations beyond standard regimens did not improve overall neurological outcomes or survival rates. Notably, the trial demonstrated higher-than-expected survival among nonshockable cardiac arrest patients, with delayed neurological recovery observed up to two weeks post-arrest. The authors conclude that extending hypothermia duration up to 72 hours offers no added neurological benefit, though subgroup analyses remain ongoing to determine whether specific patient phenotypes derive differential benefit from tailored cooling durations.

Link to the article: https://jamanetwork.com/journals/jama/article-abstract/2852508

References

Meurer, W. J., Yeatts, S. D., Geocadin, R. G., Roy, A., Callaway, C. W., Ramakrishnan, V., Berry, S. M., Caveney, A. F., Meyer, S., Bozeman, N., Harney, D. M., Speers, M., Stevenson, V. L. W., Sozener, C. B., Daya, M. R., Beiser, D. G., Elmer, J., Khan, I. R., Hirsch, K. G., … Marion, J. (2026). Duration of therapeutic hypothermia after out-of-hospital cardiac arrest: The icecap randomized clinical trial. JAMA. https://doi.org/10.1001/jama.2026.10247